(Q37918893)

25 August 2017

1 reference

title

Combination of targeted therapy and immunotherapy in melanoma (English)

1 reference

25 August 2017

1 reference

1

Christian U Blank

1 reference

25 August 2017

4

Ton N Schumacher

1 reference

25 August 2017

Anna I Hooijkaas

2

1 reference

PubMed ID

21847631

25 August 2017

John B Haanen

series ordinal

3

1 reference

PubMed ID

21847631

25 August 2017

language of work or name

1 reference

17 August 2011

1 reference

Cancer Immunology, Immunotherapy

25 August 2017

1 reference

25 August 2017

60

1 reference

25 August 2017

1359-1371

1 reference

25 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-011-1079-2

25 August 2017

0 references

cites work

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Current systemic therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

The INK4a/ARF locus and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Molecular pathogenesis of cutaneous melanocytic neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Understanding melanoma signaling networks as the basis for molecular targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Melanoma--an unlikely poster child for personalized cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Spontaneous regression of metastases from melanoma: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

CD28 and CTLA-4 coreceptor expression and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

PD-1 signaling in primary T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Down-regulation of the macrophage lineage through interaction with OX2 (CD200)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

TNF/TNFR family members in costimulation of T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

The role of TNF superfamily members in T-cell function and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Immune regulatory antibodies: are they the next advance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

High-throughput T-cell epitope discovery through MHC peptide exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

BRAF, a target in melanoma: implications for solid tumor drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

Phase I/II trial of tremelimumab in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1079-2

10.1007/S00262-011-1079-2

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

21847631